{
  "locale": "en",
  "category": "metabolic",
  "generatedAt": "2025-12-27T03:34:57.574Z",
  "count": 6,
  "diseases": [
    {
      "id": "diabetes-mellitus-2",
      "titulo": "Type 2 Diabetes Mellitus (T2DM)",
      "sinonimos": [
        "Type 2 Diabetes",
        "T2DM",
        "Adult-Onset Diabetes"
      ],
      "doid": "DOID:9351",
      "snomedCT": "44054006",
      "meshId": "D003924",
      "umlsCui": "C0011860",
      "ciap2": [
        "T90"
      ],
      "cid10": [
        "E11"
      ],
      "categoria": "metabolic",
      "quickView": {
        "definicao": "A metabolic disorder characterized by chronic hyperglycemia resulting from defects in insulin secretion and/or action. It represents 90-95% of diabetes cases and is strongly associated with obesity and sedentary lifestyle.",
        "criteriosDiagnosticos": [
          "Fasting glucose ≥126 mg/dL (confirmed on 2 occasions)",
          "2-hour post-OGTT 75g glucose ≥200 mg/dL",
          "HbA1c ≥6.5% (certified method)",
          "Casual glucose ≥200 mg/dL + classic symptoms (polyuria, polydipsia, weight loss)"
        ],
        "tratamentoPrimeiraLinha": {
          "naoFarmacologico": [
            "Diet: caloric reduction if overweight, complex carbohydrates, fiber",
            "Physical activity: 150 min/week aerobic + resistance 2-3x",
            "Weight loss of 7-10% if overweight/obese",
            "Diabetes education and self-monitoring",
            "Smoking cessation"
          ],
          "farmacologico": [
            "Metformin 500-2550mg/day (first line if GFR >30)",
            "If HbA1c >7.5% or symptomatic: add second agent",
            "SGLT2 inhibitors if CVD or CKD (empagliflozin, dapagliflozin)",
            "GLP-1 agonists if obesity or CVD (semaglutide, liraglutide)",
            "Insulin if HbA1c >10% or severe symptoms"
          ]
        },
        "metasTerapeuticas": [
          "HbA1c <7% (general)",
          "HbA1c <6.5% if recently diagnosed, young, no hypoglycemia",
          "HbA1c <8% if frail elderly, comorbidities, hypoglycemia risk",
          "Fasting glucose 80-130 mg/dL",
          "Postprandial glucose <180 mg/dL"
        ],
        "examesIniciais": [
          "HbA1c (every 3-6 months)",
          "Fasting glucose",
          "Lipid profile (LDL, HDL, TG)",
          "Creatinine and GFR",
          "Urine albumin/creatinine ratio",
          "Fundus examination",
          "Foot examination (sensitivity, pulses)",
          "ECG"
        ],
        "redFlags": [
          "Diabetic ketoacidosis (glucose >250, ketonuria, acidosis)",
          "Hyperosmolar hyperglycemic state (glucose >600, severe dehydration)",
          "Severe hypoglycemia (<54 mg/dL with neurological symptoms)",
          "Severe infection (infected diabetic foot, sepsis)",
          "Acute coronary syndrome"
        ]
      },
      "fullContent": {
        "epidemiologia": {
          "prevalencia": "9.4% of the Brazilian adult population (~16 million)",
          "incidencia": "~500,000 new cases/year",
          "mortalidade": "~70,000 deaths/year attributed to DM",
          "faixaEtaria": "Peak 45-64 years, increasing in younger individuals",
          "fatoresRisco": [
            "Obesity/overweight (BMI ≥25)",
            "Sedentary lifestyle",
            "Family history of DM",
            "Prediabetes (fasting glucose 100-125, OGTT 140-199, HbA1c 5.7-6.4%)",
            "Previous gestational diabetes",
            "Polycystic ovary syndrome",
            "HTN, dyslipidemia",
            "Use of corticosteroids, antipsychotics"
          ],
          "citations": [
            {
              "refId": "sbd-2024"
            }
          ]
        },
        "quadroClinico": {
          "sintomasPrincipais": [
            "Often oligosymptomatic or asymptomatic",
            "Polyuria (frequent urination)",
            "Polydipsia (excessive thirst)",
            "Unintentional weight loss",
            "Fatigue",
            "Blurred vision",
            "Recurrent infections (candidiasis, UTIs)"
          ],
          "sinaisExameFisico": [
            "Central obesity (increased waist circumference)",
            "Acanthosis nigricans (neck, armpits)",
            "Sensory changes in feet (neuropathy)",
            "Diminished pedal pulses (PAD)",
            "Retinopathy on fundus examination"
          ],
          "citations": [
            {
              "refId": "sbd-2024"
            }
          ]
        },
        "diagnostico": {
          "criterios": [
            "Fasting glucose ≥126 mg/dL (2 occasions or 1 + symptoms)",
            "2-hour OGTT 75g glucose ≥200 mg/dL",
            "HbA1c ≥6.5%",
            "Casual glucose ≥200 + classic symptoms"
          ],
          "diagnosticoDiferencial": [
            "Type 1 diabetes (autoimmune, absolute insulin deficiency)",
            "LADA (late autoimmune diabetes)",
            "MODY (genetic)",
            "Secondary diabetes (pancreatitis, Cushing's, medications)"
          ],
          "examesLaboratoriais": [
            "HbA1c, fasting glucose",
            "Lipid profile",
            "Creatinine, GFR, urine albumin/creatinine ratio",
            "Transaminases",
            "TSH"
          ],
          "citations": [
            {
              "refId": "sbd-2024"
            }
          ]
        },
        "tratamento": {
          "objetivos": [
            "Achieve and maintain individualized glycemic targets",
            "Prevent micro and macrovascular complications",
            "Reduce cardiovascular mortality",
            "Improve quality of life"
          ],
          "naoFarmacologico": {
            "medidas": [
              "Individualized nutritional therapy",
              "Reduction of simple carbohydrates and sugar",
              "Increase in fiber, vegetables, proteins",
              "Physical activity: 150 min/week aerobic + resistance",
              "Weight loss of 7-10% if overweight",
              "Structured diabetes education",
              "Capillary glucose self-monitoring"
            ],
            "citations": [
              {
                "refId": "sbd-2024"
              }
            ]
          },
          "farmacologico": {
            "primeiraLinha": [
              {
                "classe": "Biguanide",
                "medicamentos": [
                  "Metformin 500-2550mg/day"
                ],
                "posologia": "2-3x/day with meals (XR 1x/day)",
                "observacoes": "Start with 500mg 1-2x/day, titrate every 1-2 weeks. Contraindicated: GFR <30, acidosis, dehydration"
              }
            ],
            "segundaLinha": [
              {
                "classe": "SGLT2 inhibitors",
                "medicamentos": [
                  "Empagliflozin 10-25mg/day",
                  "Dapagliflozin 10mg/day"
                ],
                "observacoes": "Prefer if atherosclerotic CVD or HF or CKD. Contraindicated: GFR <20-25"
              },
              {
                "classe": "GLP-1 agonist",
                "medicamentos": [
                  "Semaglutide 0.25-1mg SC/week",
                  "Liraglutide 0.6-1.8mg SC/day"
                ],
                "observacoes": "Prefer if obesity or CVD. High cost, not available in SUS"
              },
              {
                "classe": "Sulfonylurea",
                "medicamentos": [
                  "Glibenclamide 2.5-20mg/day",
                  "Gliclazide MR 30-120mg/day"
                ],
                "observacoes": "Available in SUS. Risk of hypoglycemia and weight gain"
              },
              {
                "classe": "Insulin",
                "medicamentos": [
                  "NPH 10 U at night",
                  "Regular preprandial"
                ],
                "observacoes": "If HbA1c >10%, catabolic symptoms, failure of OADs"
              }
            ],
            "situacoesEspeciais": [
              {
                "situacao": "Established CVD",
                "conduta": "Prefer SGLT2 inhibitors or GLP-1 agonists with proven CV benefit"
              },
              {
                "situacao": "HF",
                "conduta": "SGLT2 inhibitors mandatory (empagliflozin, dapagliflozin)"
              },
              {
                "situacao": "CKD",
                "conduta": "SGLT2 inhibitors if GFR >20-25. Adjust metformin/suspend if GFR <30"
              },
              {
                "situacao": "Frail elderly",
                "conduta": "Target HbA1c <8%. Avoid sulfonylureas. Prefer DPP-4 inhibitors"
              }
            ],
            "citations": [
              {
                "refId": "sbd-2024"
              }
            ]
          },
          "duracao": "Continuous and progressive treatment"
        },
        "acompanhamento": {
          "frequenciaConsultas": "Every 3-4 months if uncontrolled; 6 months if stable",
          "examesControle": [
            "HbA1c every 3-6 months",
            "Lipid profile, creatinine, GFR, microalbuminuria: annually",
            "Fundus examination: annually (every 2 years if no retinopathy and good control)",
            "Foot examination: at each visit",
            "ECG: annually if >40 years or risk factors"
          ],
          "metasTerapeuticas": [
            "Individualized HbA1c (generally <7%)",
            "BP <130/80 mmHg",
            "LDL <100 mg/dL (or <70 if high CV risk)",
            "Smoking cessation",
            "Healthy weight"
          ],
          "criteriosEncaminhamento": [
            "Diabetic retinopathy (to ophthalmology)",
            "Diabetic foot with lesion/infection",
            "CKD GFR <30 or progressive albuminuria",
            "Refractory decompensation",
            "Complex insulinization required"
          ],
          "citations": [
            {
              "refId": "sbd-2024"
            }
          ]
        },
        "prevencao": {
          "primaria": [
            "Identification and treatment of prediabetes",
            "Lifestyle change program",
            "Metformin in high-risk prediabetes"
          ],
          "secundaria": [
            "Adequate glycemic control",
            "Screening and treatment of complications",
            "Vaccination (influenza, pneumococcus, hepatitis B)"
          ],
          "citations": [
            {
              "refId": "sbd-2024"
            }
          ]
        }
      },
      "protocolos": [
        "protocolo-dm2",
        "insulinizacao-dm2"
      ],
      "medicamentos": [
        "metformina",
        "glibenclamida",
        "insulina-nph",
        "empagliflozina"
      ],
      "calculadoras": [
        "findrisc",
        "ckdepi",
        "framingham"
      ],
      "rastreamentos": [
        "diabetes-mellitus-2"
      ],
      "citations": [
        {
          "refId": "sbd-2024"
        }
      ],
      "lastUpdate": "2024-12",
      "tags": [
        "metabolic",
        "chronic",
        "prevalent",
        "dcnt"
      ]
    },
    {
      "id": "obesidade",
      "titulo": "Obesity",
      "sinonimos": [
        "Excess weight",
        "Overweight"
      ],
      "doid": "DOID:9970",
      "snomedCT": "414916001",
      "meshId": "D009765",
      "umlsCui": "C0028754",
      "ciap2": [
        "T82",
        "T83"
      ],
      "cid10": [
        "E66",
        "E66.0",
        "E66.9"
      ],
      "cid11": [
        "5B81"
      ],
      "categoria": "metabolic",
      "quickView": {
        "definicao": "A chronic disease characterized by excessive accumulation of body fat, with negative health consequences. Defined by BMI ≥30 kg/m².",
        "criteriosDiagnosticos": [
          "BMI ≥25 kg/m²: overweight",
          "BMI ≥30 kg/m²: obesity grade I",
          "BMI ≥35 kg/m²: obesity grade II",
          "BMI ≥40 kg/m²: obesity grade III (morbid)",
          "Waist circumference: >94cm (M) or >80cm (F) - increased risk"
        ],
        "tratamentoPrimeiraLinha": {
          "naoFarmacologico": [
            "Lifestyle modification (Lifestyle Changes) is the foundation of treatment",
            "Hypocaloric diet (500-1000 kcal/day deficit)",
            "Physical activity: 150-300 min/week of aerobic exercise",
            "Cognitive-behavioral therapy",
            "Nutritional support with a dietitian"
          ],
          "farmacologico": [
            "Consider if BMI ≥30, or BMI ≥27 with comorbidity",
            "After failure of lifestyle changes for 3-6 months",
            "Options: Orlistate, Semaglutide, Liraglutide, Sibutramine (with restrictions)",
            "Bariatric surgery if BMI ≥40 or ≥35 with severe comorbidity"
          ]
        },
        "metasTerapeuticas": [
          "5-10% weight loss in 6 months (clinically significant)",
          "Improvement of comorbidities (DM, HTN, dyslipidemia)",
          "Long-term weight maintenance",
          "Improvement in quality of life"
        ],
        "examesIniciais": [
          "Fasting glucose, HbA1c",
          "Lipid profile",
          "Liver function (steatosis)",
          "TSH (to rule out hypothyroidism)",
          "Renal function",
          "Uric acid"
        ],
        "redFlags": [
          "Rapid and unexplained weight gain",
          "Cushing's syndrome (moon face, purple striae)",
          "Severe sleep apnea",
          "Idiopathic intracranial hypertension",
          "Severe metabolic syndrome"
        ]
      },
      "fullContent": {
        "epidemiologia": {
          "prevalencia": "30% of Brazilian adults (obesity), 55% overweight",
          "incidencia": "Growing global pandemic",
          "faixaEtaria": "All ages, increases in middle age",
          "fatoresRisco": [
            "Hypercaloric and ultra-processed diet",
            "Sedentary lifestyle",
            "Genetics (60-70% heritability)",
            "Socioeconomic factors",
            "Sleep disorders",
            "Chronic stress",
            "Medications (corticosteroids, antipsychotics, some antidepressants)"
          ],
          "citations": [
            {
              "refId": "abeso-2022"
            }
          ]
        },
        "fisiopatologia": {
          "texto": "Chronic imbalance between energy intake and expenditure, modulated by genetic, environmental, hormonal, and psychological factors. Adipose tissue is not inert: it secretes adipokines that promote low-grade chronic inflammation, insulin resistance, and metabolic dysfunction.",
          "citations": [
            {
              "refId": "abeso-2022"
            }
          ]
        },
        "quadroClinico": {
          "sintomasPrincipais": [
            "Visible excess weight",
            "Dyspnea on exertion",
            "Fatigue",
            "Joint pain (knees, spine)",
            "Snoring, sleep apnea",
            "Low self-esteem"
          ],
          "sinaisExameFisico": [
            "Elevated BMI",
            "Increased waist circumference",
            "Acanthosis nigricans (insulin resistance)",
            "Striae",
            "Edema of the lower extremities"
          ],
          "formasClinicas": [
            "Android obesity (central/visceral): higher metabolic risk",
            "Gynoid obesity (peripheral): lower metabolic risk"
          ],
          "citations": [
            {
              "refId": "abeso-2022"
            }
          ]
        },
        "diagnostico": {
          "criterios": [
            "BMI ≥30 kg/m² (obesity)",
            "Increased waist circumference",
            "Evaluation of associated comorbidities"
          ],
          "diagnosticoDiferencial": [
            "Edema (anasarca)",
            "Hypothyroidism",
            "Cushing's syndrome",
            "Medication use",
            "Rare genetic syndromes"
          ],
          "examesLaboratoriais": [
            "Fasting glucose, HbA1c, OGTT",
            "Complete lipid profile",
            "Liver function, abdominal ultrasound (steatosis)",
            "TSH",
            "Renal function, uric acid",
            "ECG, echocardiogram if indicated"
          ],
          "citations": [
            {
              "refId": "abeso-2022"
            }
          ]
        },
        "tratamento": {
          "objetivos": [
            "Sustained weight loss",
            "Improvement of comorbidities",
            "Prevention of complications",
            "Improvement in quality of life"
          ],
          "naoFarmacologico": {
            "medidas": [
              "Balanced hypocaloric diet (500-1000 kcal/day deficit)",
              "Physical activity: 150-300 min/week aerobic + resistance",
              "Cognitive-behavioral therapy",
              "Multidisciplinary team follow-up"
            ],
            "citations": [
              {
                "refId": "abeso-2022"
              }
            ]
          },
          "farmacologico": {
            "primeiraLinha": [
              {
                "classe": "Lipase inhibitor",
                "medicamentos": [
                  "Orlistate"
                ],
                "posologia": "120mg three times daily with main meals"
              },
              {
                "classe": "GLP-1 agonist",
                "medicamentos": [
                  "Semaglutide",
                  "Liraglutide"
                ],
                "posologia": "Semaglutide SC: start at 0.25mg/week, titrate to 2.4mg/week"
              }
            ],
            "situacoesEspeciais": [
              {
                "situacao": "BMI ≥40 or ≥35 with severe comorbidity",
                "conduta": "Evaluate for bariatric surgery"
              },
              {
                "situacao": "Obesity + T2DM",
                "conduta": "Prefer GLP-1 agonists or SGLT2 inhibitors"
              }
            ],
            "citations": [
              {
                "refId": "abeso-2022"
              }
            ]
          },
          "duracao": "Chronic treatment"
        },
        "acompanhamento": {
          "frequenciaConsultas": "Monthly for the first 6 months, then every 3 months",
          "examesControle": [
            "Weight, BMI, waist circumference",
            "Glucose, HbA1c",
            "Lipid profile",
            "Liver function"
          ],
          "metasTerapeuticas": [
            "5-10% weight loss from initial weight is clinically significant",
            "Maintenance of lost weight"
          ],
          "criteriosEncaminhamento": [
            "Evaluation for bariatric surgery",
            "Suspected secondary cause",
            "Severe complications"
          ],
          "citations": [
            {
              "refId": "abeso-2022"
            }
          ]
        },
        "prevencao": {
          "primaria": [
            "Healthy diet from childhood",
            "Regular physical activity",
            "Reduction of ultra-processed foods"
          ],
          "secundaria": [
            "Early intervention in overweight",
            "Treatment of comorbidities"
          ],
          "citations": [
            {
              "refId": "abeso-2022"
            }
          ]
        }
      },
      "protocolos": [
        "protocolo-obesidade"
      ],
      "medicamentos": [
        "orlistate",
        "semaglutide",
        "liraglutide"
      ],
      "calculadoras": [
        "imc",
        "risco-cv"
      ],
      "rastreamentos": [],
      "citations": [
        {
          "refId": "abeso-2022"
        }
      ],
      "lastUpdate": "2024-12",
      "tags": [
        "obesity",
        "overweight",
        "bmi",
        "weight-loss",
        "bariatric-surgery"
      ]
    },
    {
      "id": "nodulo-tireoide",
      "titulo": "Thyroid Nodule",
      "ciap2": [
        "T81"
      ],
      "cid10": [
        "E04"
      ],
      "cid11": [
        "5A00.1"
      ],
      "categoria": "metabolic",
      "doid": "DOID:50",
      "snomedCT": "237495005",
      "meshId": "D016606",
      "umlsCui": "C0040137",
      "quickView": {
        "definicao": "Discrete lesions in the thyroid, very common (50% of the population by ultrasound). Most are benign. 5-15% are carcinomas.",
        "criteriosDiagnosticos": [
          "Palpable nodule or incidental finding on imaging",
          "TSH to assess function",
          "Thyroid ultrasound for characterization",
          "Fine-needle aspiration biopsy if >1cm with suspicious features"
        ],
        "tratamentoPrimeiraLinha": {
          "naoFarmacologico": [
            "Observation if benign and small",
            "Periodic follow-up with ultrasound"
          ],
          "farmacologico": [
            "No pharmacological treatment for benign nodules",
            "Levotiroxine does NOT suppress nodules"
          ]
        },
        "redFlags": [
          "Rapid growth",
          "Hoarseness",
          "Hard nodule",
          "Cervical lymphadenopathy",
          "Family history of thyroid cancer"
        ]
      },
      "medicamentos": [],
      "protocolos": [],
      "calculadoras": []
    },
    {
      "id": "dislipidemia",
      "titulo": "Dyslipidemia",
      "sinonimos": [
        "Hyperlipidemia",
        "Hypercholesterolemia",
        "Hypertriglyceridemia"
      ],
      "ciap2": [
        "T93"
      ],
      "cid10": [
        "E78.0",
        "E78.1",
        "E78.2",
        "E78.5"
      ],
      "cid11": [
        "5C80"
      ],
      "doid": "DOID:1168",
      "snomedCT": "370992007",
      "meshId": "D050171",
      "umlsCui": "C0242339",
      "categoria": "metabolic",
      "quickView": {
        "definicao": "Alteration in lipid metabolism with elevated LDL-c, triglycerides, and/or reduced HDL-c. The main modifiable risk factor for atherosclerotic cardiovascular disease.",
        "criteriosDiagnosticos": [
          "LDL-c ≥160 mg/dL (high) or ≥130 mg/dL (borderline)",
          "HDL-c <40 mg/dL (men) or <50 mg/dL (women)",
          "Triglycerides ≥150 mg/dL",
          "Total cholesterol ≥240 mg/dL",
          "Calculate cardiovascular risk (ASCVD, Framingham)"
        ],
        "tratamentoPrimeiraLinha": {
          "naoFarmacologico": [
            "Mediterranean diet or DASH",
            "Aerobic exercise 150 min/week",
            "Weight loss if overweight/obese",
            "Smoking cessation",
            "Reduce alcohol"
          ],
          "farmacologico": [
            "Statins: Simvastatin 20-40mg, Atorvastatin 10-80mg, Rosuvastatin 5-20mg",
            "Target LDL-c according to risk: <70 (very high), <100 (high), <130 (moderate)",
            "Ezetimibe 10mg if target not achieved with statin",
            "Fibrate if TG >500 mg/dL"
          ]
        },
        "redFlags": [
          "Xanthomas",
          "Corneal arcus <45 years",
          "Family history of early CV event",
          "Pancreatitis (TG>1000)"
        ],
        "metasTerapeuticas": [
          "Reduction of 30-50% in LDL-c or absolute target according to risk"
        ],
        "examesIniciais": [
          "Fasting lipid profile",
          "Glucose",
          "Creatinine",
          "TSH",
          "AST/ALT"
        ]
      },
      "protocolos": [
        "has",
        "dm2"
      ],
      "medicamentos": [
        "sinvastatina",
        "atorvastatina",
        "rosuvastatina"
      ],
      "calculadoras": [
        "risco-cardiovascular"
      ],
      "tags": [
        "cardiovascular",
        "prevention",
        "statin"
      ]
    },
    {
      "id": "deficiencia-vitamina-d",
      "titulo": "Vitamin D Deficiency",
      "sinonimos": [
        "Hypovitaminosis D",
        "Vitamin D Insufficiency"
      ],
      "ciap2": [
        "T91"
      ],
      "cid10": [
        "E55.9"
      ],
      "cid11": [
        "5B57.4"
      ],
      "doid": "DOID:10609",
      "snomedCT": "34713006",
      "meshId": "D014808",
      "umlsCui": "C0042870",
      "categoria": "metabolic",
      "quickView": {
        "definicao": "Insufficient levels of 25(OH)D associated with bone impairment and possible extraskeletal effects. Prevalence >50% in some populations.",
        "criteriosDiagnosticos": [
          "25(OH)D <20 ng/mL: Deficiency",
          "25(OH)D 20-29 ng/mL: Insufficiency",
          "25(OH)D ≥30 ng/mL: Sufficiency",
          "Screen risk groups: elderly, obese, dark-skinned, low sun exposure"
        ],
        "tratamentoPrimeiraLinha": {
          "naoFarmacologico": [
            "Moderate sun exposure (10-15 min/day)",
            "Fortified foods",
            "Fatty fish, egg yolk"
          ],
          "farmacologico": [
            "Deficiency: Colecalciferol 50,000 IU/week for 8 weeks",
            "Maintenance: 1,000-2,000 IU/day",
            "Elderly/obese may require higher doses"
          ]
        },
        "redFlags": [
          "Symptomatic hypocalcemia",
          "Fragility fractures",
          "Osteomalacia"
        ],
        "metasTerapeuticas": [
          "25(OH)D ≥30 ng/mL"
        ],
        "examesIniciais": [
          "Serum 25(OH)D",
          "Calcium, phosphorus",
          "PTH",
          "Creatinine"
        ]
      },
      "protocolos": [],
      "medicamentos": [
        "colecalciferol"
      ],
      "calculadoras": [],
      "tags": [
        "bone",
        "supplementation",
        "screening"
      ]
    },
    {
      "id": "hiperuricemia-assintomatica",
      "titulo": "Asymptomatic Hyperuricemia",
      "sinonimos": [
        "Elevated uric acid"
      ],
      "ciap2": [
        "T99"
      ],
      "cid10": [
        "E79.0"
      ],
      "cid11": [
        "5C64.0"
      ],
      "doid": "DOID:9245",
      "snomedCT": "35885006",
      "meshId": "D033461",
      "umlsCui": "C0740394",
      "categoria": "metabolic",
      "quickView": {
        "definicao": "Elevated serum uric acid (>7 mg/dL in men, >6 mg/dL in women) without a history of gout or urate nephrolithiasis.",
        "criteriosDiagnosticos": [
          "Uric acid >7 mg/dL (M) or >6 mg/dL (F)",
          "Absence of gouty arthritis",
          "Absence of urate nephrolithiasis",
          "Evaluate comorbidities: hypertension, chronic kidney disease, metabolic syndrome"
        ],
        "tratamentoPrimeiraLinha": {
          "naoFarmacologico": [
            "Weight reduction",
            "Limit alcohol (especially beer)",
            "Avoid sugary drinks",
            "Reduce red meat and offal",
            "Increase low-fat dairy"
          ],
          "farmacologico": [
            "DO NOT treat based on uric acid level alone",
            "Consider treatment if: progressive chronic kidney disease, very high cardiovascular risk",
            "If indicated: Alopurinol 100mg, titrate to target",
            "Febuxostat as an alternative"
          ]
        },
        "redFlags": [
          "First episode of gout",
          "Urate nephrolithiasis",
          "Urate nephropathy",
          "Tumor lysis syndrome"
        ],
        "metasTerapeuticas": [
          "Uric acid <6 mg/dL if treated"
        ],
        "examesIniciais": [
          "Serum uric acid",
          "Creatinine",
          "Lipid profile",
          "Blood glucose",
          "Complete blood count"
        ]
      },
      "protocolos": [],
      "medicamentos": [
        "alopurinol"
      ],
      "calculadoras": [],
      "tags": [
        "gout",
        "renal",
        "metabolic"
      ]
    }
  ]
}